Shankar Vallabhajosula, Ph.D.

President and Chief Scientific Officer (CSO)
Dr. Vallabhajosula served as an advisor and consultant to NCM-USA for many years and finally took over as the President and CSO in January 2017.

As a research scientist in the field of nuclear medicine with 40 years of experience, Dr. Vallabhajosula pioneered the development of radiopharmaceuticals for non-invasive imaging studies and targeted radionuclide therapy. His major areas of research interest are in oncology, cardiology and neuro-psychiatric diseases.

In 980, Dr. Shankar received his Ph.D. in Biomedicinal Chemistry (with specialization in Radiopharmacy) from the University of Southern California, Los Angeles, CA.  After working for 17 years at Mount Sinai School of Medicine in New York, he joined Weill Cornell Medicine in 1997 as a professor of radiochemistry/radiopharmacy in radiology. He established the cyclotron/radiochemistry program at the Citigroup Biomedical Imaging Center (CBIC) of Weill Cornell Medicine of Cornell University. Under his direction, Cornell received NDA (new drug application) in 2004 for the manufacture of Fludeoxyglucose F18 injection (FDG).

Dr. Vallabhajosula received “Berson-Yalow Award” from the Greater New York Chapter, Society of Nuclear Medicine for his contributions to the science of Nuclear Medicine. In 2009, he published a single author text book on “Molecular Imaging: Radiopharmaceuticals for PET and SPECT(Springer 2009). Dr. Vallabhajosula published more than 100 scientific articles in peer-reviewed journals and presented more than 200 abstracts in major National and International Conferences.

FDA Approved PET Radiopharmaceuticals
Cyclotron Produced Radionuclides and Radiochemicals
Contract Manufacturing of IND Radiopharmaceuticals
Research and Development
Educational Materials
Radionuclide Therapy
Radionuclide Therapy